Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: Diagnostic and prognostic significance

Leukemia

Volumn 28, Issue 4, 2014, Pages 865-870

  Kwong, Y L ^a   Pang, A W K ^a   Leung, A Y H ^a   Chim, C S ^a   Tse, E ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Epstein Barr virus DNA; NK T cell lymphoma; prognosis; SMILE

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CHEMOSENSITIVITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; KOREAN PROGNOSTIC SCORE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEOPLASM; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOAD; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; DEXAMETHASONE; DNA, VIRAL; ETOPOSIDE; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IFOSFAMIDE; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS;

EID: 84898491167     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.212     Document Type: Article

References (16)

1. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL et al. (eds) WHO classification of tumours of haematopoeitic and lymphoid tissue. International Agency for Research on Cancer: Lyon, 2008, pp 285-288.
2. Chan JK, Jaffe ES, Ralfkiaer E, Ko YH. Aggresssive NK cell leukaemia. In: Swerdlow SH, Campo E, Harris NL et al. (eds) WHO classification of tumours of haematopoeitic and lymphoid tissue. International Agency for Research on Cancer: Lyon, 2008, pp 276-277.
3. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19: 2186-2194.
4. Ishida F, Kwong YL. Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol 2010; 3: 593-602.
5. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 1016-1020. (Pubitemid 351997606)
6. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011; 29: 4410-4416.
7. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012; 120: 2973-2980.
8. Lo YM. Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. Ann N Y Acad Sci 2001; 945: 68-72. (Pubitemid 33022433)
9. Fryer JF, Heath AB, Wilkinson DE, Minor PD. the Collaborative Study Group. Collaborative study to evaluate the proposed 1st WHO international standard for Epstein-Barr Virus (EBV) for nucleic acid amplification technology (NAT)-based assays). http://www.who.int/biologicals/expert-committee/BS2011. 2172Epstein-Barr-Virus.pdf (accessed on 26 January 2013)
10. National Institute for Biological Standards and Control. WHO International Standard. 1st WHO international standard for Epstein-Barr Virus for nucleic acid amplification techniques NIBSC code: 09/260. Instructions for use (Version 2.0, Dated 12/01/2012). http://www.nibsc.ac.uk/documents/ifu/09- 260.pdf (accessed on 26 January 2013).
11. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618. (Pubitemid 46630424)
12. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216-221. (Pubitemid 38029941)
13. Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res 2012; 18: 4183-4190.
14. Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim do H et al. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma 2009; 50: 757-763.
15. Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y et al. NK-cell Tumor Study Group. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 2011; 118: 6018-6022.
16. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243-249. (Pubitemid 38879864)